214 related articles for article (PubMed ID: 34911334)
21. Primary breast lymphoma: A single-centre experience.
Foo MY; Lee WP; Seah CMJ; Kam C; Tan SM
Cancer Rep (Hoboken); 2019 Feb; 2(1):e1140. PubMed ID: 32721093
[TBL] [Abstract][Full Text] [Related]
22. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
23. Diffuse large B-cell lymphoma involving the left sternoclavicular joint mimicking rheumatoid arthritis flare: a case-based review.
Chung SW; Park EH; Kang EH; Lee YJ; Ha YJ
Rheumatol Int; 2020 Apr; 40(4):651-655. PubMed ID: 32036399
[TBL] [Abstract][Full Text] [Related]
24. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M; Gandhi MK; Trotman J; Butcher B; Taper J; Johnston A; Gill D; Ho SJ; Cull G; Fay K; Chong G; Grigg A; Lewis ID; Milliken S; Renwick W; Hahn U; Filshie R; Kannourakis G; Watson AM; Warburton P; Wirth A; Seymour JF; Hofman MS; Hicks RJ;
Haematologica; 2017 Feb; 102(2):356-363. PubMed ID: 28143954
[TBL] [Abstract][Full Text] [Related]
25. Primary diffuse large B-cell lymphoma of the Larynx.
Higo R; Kojima M; Itoh S; Noguchi M; Izumi H; Takeuchi K
Auris Nasus Larynx; 2023 Aug; 50(4):632-636. PubMed ID: 35863932
[TBL] [Abstract][Full Text] [Related]
26. 25 Years Old Women With Inflammatory Low Back Pain.
Soltani Z; Davatchi F
Med Arch; 2016 Jun; 70(3):219-22. PubMed ID: 27594751
[TBL] [Abstract][Full Text] [Related]
27. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
[TBL] [Abstract][Full Text] [Related]
28. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
29. The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients.
Park LC; Song YJ; Kim DJ; Kim MJ; Jo JC; Lee WS; Shin HJ; Oh SY; Do YR; Jeong JY; Lee HS;
Int J Cancer; 2019 Nov; 145(9):2459-2467. PubMed ID: 30973963
[TBL] [Abstract][Full Text] [Related]
30. Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients.
Koh YW; Hwang HS; Park CS; Yoon DH; Suh C; Huh J
Leuk Lymphoma; 2015; 56(9):2630-6. PubMed ID: 25573205
[TBL] [Abstract][Full Text] [Related]
31. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
33. Rare case of primary bone lymphoma of the femur.
Kiamos A; Boldig K; Gagadam V; Gujarathi R
BMJ Case Rep; 2023 Jul; 16(7):. PubMed ID: 37474139
[TBL] [Abstract][Full Text] [Related]
34. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
35. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
Persky DO; Li H; Stephens DM; Park SI; Bartlett NL; Swinnen LJ; Barr PM; Winegarden JD; Constine LS; Fitzgerald TJ; Leonard JP; Kahl BS; LeBlanc ML; Song JY; Fisher RI; Rimsza LM; Smith SM; Miller TP; Friedberg JW
J Clin Oncol; 2020 Sep; 38(26):3003-3011. PubMed ID: 32658627
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Jul; 170(2):185-91. PubMed ID: 25833790
[TBL] [Abstract][Full Text] [Related]
37. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
38. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
[TBL] [Abstract][Full Text] [Related]
39. Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP.
Lee JY; Kang M; Suh KJ; Kim JW; Kim SH; Kim JW; Kim YJ; Song KH; Kim ES; Kim HB; Lee KW; Kim JH; Bang SM; Lee JS; Lee JO
Mycoses; 2021 Jan; 64(1):60-65. PubMed ID: 32970331
[TBL] [Abstract][Full Text] [Related]
40. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
